Increased attention on the epidemic of asthma in the past year has focused on education, pharmacologic therapy, community outreach, and spacers, with some curbing of the high prevalence in East Harlem. We assessed what asthma patients utilize outside of standard therapy in the context of their culture. Methods: The literature was searched for complementary/alternative medicines(CAM) used for asthma. We piloted a 9-item semi-open questionnaire in English/Spanish and surveyed 15 patients/caregivers. The pharmacologic basis for the reported agents was used to develop a clinical database. Educational literature will teach clinicians and patients, advising putative drug-drug interactions. Results: Extensive pharmacology and clinical information on CAM exists in US databases. Clinical trials were found internationally and in other medical systems. A clinical NIH/CAM Center devoted to asthma/immunology exists, as well as a NIH consensus statement on the effective adjunct use of acupuncture. Eleven of 15 surveyed revealed names of agents and patterns of usage common in the Mexican and Caribbean communities when asked in a culturally sensitive way. Drug mechanisms were found for 12 of 19 agents identified, using standard pharmacognosy and pharmacology sources. Conclusions: Clinical information on CAM approaches to asthma, with scientific mechanisms of action exist. Survey yield is highly dependent upon the nature of discussion on daily adherence to asthma therapy. CAM therapies are most commonly used in Steps 1/ 2 asthma. MDs educated on pathophysiology are more open to CAM. Questions asked in an appropriate way move toward the goal of increasing adherence to regular clinic visits/therapy.
Learning Objectives: Recognize pharmacologic basis for botanicals used in self-management of asthma Discuss cultural issues around non-adherence to standard asthma therapy
Keywords: Asthma, Cultural Competency
Presenting author's disclosure statement:
Organization/institution whose products or services will be discussed: None
I do not have any significant financial interest/arrangement or affiliation with any organization/institution whose products or services are being discussed in this session.